Search

Displaying results 3801 - 3810 of 4233 in total
  1. Drug

    BW-A 58C

    go.drugbank.com/drugs/DB06740
    Experimental

    BW-A 58C, also known as 2-(4-tert-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone, is an experimental naphthoquinone antimalarial drug which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy

  2. Drug

    Taspoglutide

    go.drugbank.com/drugs/DB14027
    Investigational

    As of May 2013 no new trials had been registered.

  3. Drug

    Lecithin, soybean

    go.drugbank.com/drugs/DB14161
    Investigational

    complex mixture of phospholipids; glycolipids; and triglycerides; with substantial amounts of phosphatidylcholines; phosphatidylethanolamines; and phosphatidylinositols, which are sometimes loosely termed as

  4. Drug

    CIGB 2020 Vaccine

    go.drugbank.com/drugs/DB15808
    Experimental

    As of July, 2020, a Randomized control clinical trial (RPCEC00000306) is underway to evaluate prophylaxis potential in suspected contacts of Covid-19 patients.

  5. Drug

    Veru-111

    go.drugbank.com/drugs/DB16462
    Investigational

    These trials aimed to evaluate its efficacy, safety, and tolerability in conditions such as SARS-CoV-2 infection, metastatic castration-resistant prostate cancer (mCRPC), respiratory distress syndrome

  6. Drug

    Merbromin

    go.drugbank.com/drugs/DB13392
    Investigational

    Mercurochrome is a trade name of merbromin commonly used as a topical first-aid antiseptic agent.

  7. Drug

    Fostemsavir

    go.drugbank.com/drugs/DB11796
    ApprovedInvestigational

    [L14867] The discovery of gp120 as a potential target of interest in the treatment of HIV-1 infection is relatively recent, and was born out of a desire to find alternative target proteins (i.e. mechanistically

  8. Drug

    Belzutifan

    go.drugbank.com/drugs/DB15463
    ApprovedInvestigational

    [L35995] The HIF-2α protein was first identified in the 1990s by researchers at UT Southwestern Medical Center as a key player in the growth of certain cancers.

  9. Drug

    Lumefantrine co-artemether

    go.drugbank.com/drugs/DB13085
    ApprovedInvestigationalWithdrawn

    While artemether results in rapid defervescence, parasite clearance, and clinical improvement, it also has a relatively high recrudescence rate when used as monotherapy.

  10. Drug

    S-8510

    go.drugbank.com/drugs/DB06504
    Experimental

    S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.